2023-06-23 13:00:34 ET
- TRxADE HEALTH ( NASDAQ: MEDS ) said on Friday that it had signed a binding letter of intent to acquire Superlatus.
- After the closing of the deal, Superlatus shareholders will receive 30.8M shares of MEDS, valued at $7.30/share.
- Other significant closing conditions for the deal include the acquisition of Sapientia by Superlatus.
- MEDS plans to shift its focus and branding after the merger, and divest its existing operating business and assets.
- The company expects the merger to close in the late third-quarter or early fourth-quarter of 2023.
- Press Release
For further details see:
TRxADE HEALTH to acquire Superlatus